0001140361-18-030201.txt : 20180627 0001140361-18-030201.hdr.sgml : 20180627 20180627190220 ACCESSION NUMBER: 0001140361-18-030201 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180626 FILED AS OF DATE: 20180627 DATE AS OF CHANGE: 20180627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANDERSON MICHAEL S CENTRAL INDEX KEY: 0001144178 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 18922849 MAIL ADDRESS: STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 doc1.xml FORM 4 X0306 4 2018-06-26 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001144178 ANDERSON MICHAEL S BLOCK 10-1, BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN DUBLIN L2 15 IRELAND 1 1 0 0 Chief Executive Officer ADSs 2018-06-26 4 P 0 2500 6.04 A 265250 D Stock Option (right to buy) 6.93 2022-03-08 ADSs 275000 275000 D Stock Option (right to buy) 4.07 2023-02-01 ADSs 80500 80500 D Stock Option (right to buy) 16.3 2024-12-11 ADSs 200000 200000 D Stock Option (right to buy) 14.35 2025-12-10 ADSs 200000 200000 D Stock Option (right to buy) 10.4 2026-12-14 ADSs 200000 200000 D Stock Option (right to buy) 8.95 2027-12-12 ADSs 150000 150000 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.21, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; (c) 30,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and [continued in footnote 4 below] (d) 25,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 16,666 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 8,334 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant). Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date. Options became exercisable in four equal amounts over the first four anniversaries after the 02/01/2013 grant date. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date. Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/12/2017 grant date. /s/ Phillandas T. Thompson, as attorney-in-fact for Michael S. Anderson 2018-06-27